PCBL Chemical Ltd

- PCBL is not targeting any specific absolute debt level but aims to maintain a debt-to-EBITDA ratio below 2. - It might take about a year more to bring the debt-to-EBITDA ratio down to that level due to ongoing growth plans. - Surplus cash generated beyond capital expenditure will be utilized to reduce debt. - Over the next five years, PCBL expects to generate significant cash flow (~Rs. 9,500-10,000 crores), which will support both growth plans and debt reduction. - Cash flow will not be uniform annually but is expected to increase with higher capacity and sales volume. - No explicit mention of raising new equity or additional debt fundraising at this time. The focus appears to be on managing and reducing existing debt while funding CAPEX from internal accruals and cash generation.

- Aquapharm Segment: - Planned CAPEX of Rs. 600-800 crores over 3-5 years for portfolio expansion in phosphonate, polymer, and green chelates, focusing more on green products for sustainability. - Setting up a pilot plant in 6-7 months for sampling and a commercial plant of 2,000 tonnes capacity by FY '27, with plans to expand capacity up to 10,000-12,000 tonnes by 2030. - Investment split between India and USA, targeting ~25% EBITDA margin by FY '29, with scope to expand USA operations to European markets. - Carbon Black Business: - Planned CAPEX of around Rs. 2,500-2,600 crores to add approximately 430,000 tonnes capacity by 2029, aiming for 10-11% CAGR growth. - Current expansion includes 30,000 tonnes capacity addition, awaiting commissioning soon. - Supply Chain: - Continued investments in global supply chain infrastructure including new offices and warehouses to support global growth. - Overall, cash flow generation expected to support CAPEX and debt reduction over the next 3-5 years.

- Carbon Black Business: - Volume CAGR growth of 10-11% over the next 4-5 years. - Global market around 15 million tonnes with long-term growth of ~3.5% p.a. - Export volumes have increased from 150,000 to 250,000 tonnes in recent years. - Target to add ~400,000-430,000 tonnes capacity by 2029, CAPEX ~Rs. 2,500-2,600 crores. - EBITDA per ton sustainable around Rs. 21,000 with scope for improvement. - Aquapharm Segment: - Top-line growth of 17-18% from FY'26 onwards. - EBITDA margins expected to improve from ~20% next year to ~25% by FY'29. - CAPEX of Rs. 600-700 crores over 3-5 years planned to expand product portfolio. - Capacity utilization expected to increase to ~82-83% by Q4 FY'25. - Battery Chemicals: - Pilot plant approval expected within a year. - FY'27 commercial plant capacity targeted at 2,000 tonnes, with plans to scale up gradually.

- Carbon Black Business: Expected volume CAGR of 10-11% over next 5 years with capacity additions, aiming for Rs. 2,300 crore EBITDA by 2029. EBITDA per ton currently around Rs. 21,000, viewed as sustainable with scope for improvement. - Battery Chemicals: Projected incremental EBITDA of about Rs. 1,000 crore from 2,000 tonne capacity plant, with scaling potential to 10,000 tonnes; confident of market approval within a year after pilot plant operations. - Aquapharm: Anticipated top-line growth of 17-18% from FY '26 with EBITDA margin expansion from 20% rising to 25% by FY '29 through portfolio diversification and higher-margin product launches. - Overall Capex and Debt: Capex planned aligned with growth; focus on maintaining debt-to-EBITDA ratio below 2; expected cash generation to support growth and deleveraging. - Operating Efficiencies: Margins expected to benefit from operating leverage, cost reductions, and improved manufacturing yields, supporting sustainable profit growth.

The transcript provided from the PCBL Limited October 30, 2024 call does not explicitly mention details about the current or expected order book or pending orders. However, some related insights can be inferred: - The company is operating at near-full capacity (94% utilization) and plans to add new capacities soon to cater to increasing demand. - They are awaiting new approvals and customer ramp-ups after capacity expansions, indicating orders under execution. - Aquapharm segment expects recovery and expansion in European markets. - Discussions with leading battery OEMs indicate future order potential in battery chemicals. - Export sales have grown significantly, especially to Europe, constrained currently by capacity. No specific numeric values or detailed order book figures were disclosed in the provided pages.